Abstract：[Abstract]Objective To investigate the predictive efficiency of quantitative detection of Hepatitis B virus surface antigen（HBsAg）on the relapse of entecavir in patients with Hepatitis B virus antigen（HBeAg）negative chronic hepatitis B after discontinuation.Methods The clinical data of 83 outpatients with chronic hepatitis B treated with Entecavir from January 2016 to January 2017 were analyzed retrospectively，the patients were divided into relapse group（60 cases）and non relapse group（23 cases）according to the follow-up of 1 year，whether there was virological recurrence or not.The clinical data of relapse group and non relapse group were compared.The recurrence degree of HBsAg were compared in the relapse group at 6 and 12 months after drug withdrawal.Quantitative prediction of diagnostic efficacy of entecavir in relapsed group by HbsAg was analyzed.Results The baseline alanine aminotransferase（ALT），and HBsAg quantitative levels at the time of withdrawal were higher in the relapse group than those in the non-relapse group，the differences were statistically significant（P＜0.05）.There were no significant differences in gender，age，genotype，and incidence of cirrhosis and baseline Hepatitis B virus DNA（HBV DNA）between the two groups（P＞0.05）.The recurrence rate of different HBsAg quantitative levels in the relapse group at 12 months of discontinuation were higher than those at the 6 months of discontinuation，the difference was statistically significant（P＜0.05）.The area under the curve（AUC）for quantitative prediction of HBsAg discontinuation of entecavir withdrawal was 0.911（95%CI:0.828-0.962）.The optimal cutoff value for HBsAg quantification was 1.957 log10IU/ml，and the sensitivity and specificity were 85.00%and 98.00%，respectively.Conclusion Quantitative HBsAg level is more significant with the relapse time，and HBsAg quantitative detection has a higher diagnostic efficacy to predict relapse after entecavir discontinuation.
European Association for the Study of the Liver.EASL 2017 clinical practice guidelines on the management of Hepatitis B virus infection[J].J Hepatol，2017，67（2）：370-398.
Fung J，Wong T，Chok K，et al.Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation：results up to 8 years[J].Hepatology，2017，66（4）：1036-1044.
Chen CH，Hung CH，Wang JH，et al.The incidence of hepatitis B surface antigen loss between hepatitis B E antigennegative noncirrhotic patients who discontinued or continued entecavir therapy[J].J Infec Dis，2019，219（10）：1624-1633.
[10]
Wang CC，Tseng KC，Hsieh TY，et al.Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg[J].Am J Gastroenterol，2016，119（9）：1286-1294.
[11]
Lee HA，Seo YS，Park SW，et al.Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B[J].Clin Mol Hepatol，2016，22（3）：382-389.
Hung CH，Wang JH，Lu SN，et al.Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy[J].J Viral Hepat，2017，24（7）：599-607.
[14]
Ji M，Hu K.Recent advances in the study of Hepatitis B virus covalently closed circular DNA[J].Virol Sin，2017，32（6）：454-464.
[15]
Kim SH.ELISA for quantitative determination of Hepatitis B virus surface antigen[J].Immune Netw，2017，17（6）：451-459.
京公网安备 11010502046607号